MIL · BZU.MI
Buzzi S.p.A.
€40.19-€0.96 (-2.33%)
Buzzi S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 26.59% below the high.
Loading market information…
MIL · SOL.MI · EUR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 01:25 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
SOL S.p.A.’s quoted price sits in the upper half of its reported 52-week range, 6.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
SOL S.p.A.’s forward annual dividend is €0.45 per share, paid annual. The forward yield is 0.75% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
SOL S.p.A.’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SOL S.p.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SOL S.p.A., a global enterprise established in Monza, Italy, in 1927, operates as a subsidiary of Gas and Technologies World BV. The company primarily focuses on the research, manufacturing, and distribution of a diverse array of technical and medical gases, while simultaneously delivering comprehensive home healthcare solutions and associated medical equipment. Its extensive gas portfolio includes vital elements such as oxygen, nitrogen, and argon, alongside specialized gas mixtures, high-purity gases for the electronics industry, and food-grade gases. These products are supplied to various sectors including chemical, electronics, steel, metal, and food processing, as well as supporting environmental protection, scientific research, and healthcare. In the realm of home healthcare, SOL provides critical in-home therapies like oxygen, mechanical ventilation, and aerosol treatments. It also specializes in the diagnosis and management of respiratory sleep disorders, offers artificial nutrition programs, insulin pump therapy, immunotherapy, and dedicated support for pain and Parkinson's disease. Further extending its healthcare reach, the company delivers general home health and social care services, augmented by telemedicine platforms, digital health tools, and a range of healthcare aids. Beyond these core gas and home healthcare operations, SOL S.p.A. engages in a variety of complementary ventures. These encompass the design, construction, and management of biobanks; the generation and sale of hydroelectric power; and the provision of pre- and post-natal diagnostic screening. The company also develops and markets diagnostic systems and products for research and clinical applications across hospital, environmental, veterinary, and food sectors, alongside specialized bioshipping services for the secure transfer, storage, and handling of biological samples. Additional services include professional training, electromedical equipment support, hospital hygiene, environmental monitoring, and ambulance management, all facilitated by its proprietary InfoHealth SOLution web platform for operational oversight.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2022 |
|---|
| May 11, 2023 |
| €0.76 |
| €742.94M-49.21% vs estimate |
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€40.19-€0.96 (-2.33%)
Buzzi S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 26.59% below the high.
€5.46-€0.15 (-2.68%)
Industrie De Nora S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 36.35% below the high.
€2.96€0.00 (0.0%)
Franchi Umberto Marmi S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 27.98% below the high.
€5.46+€0.02 (+0.37%)
Neodecortech S.p.A.’s quoted price sits in the upper half of its reported 52-week range, 6.51% below the high.
